{"id":"W4403410372","doi":"10.1016/j.jtho.2024.09.073","title":"OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Pembrolizumab; KRAS; Oncology; Chemotherapy; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000550582,0.0004062871,0.001416463,0.0003231468,0.0002266962,0.0008374015,0.0003548067,0.0004876481,0.002764744],"category_scores_gemma":[0.0006231397,0.000206836,0.001132118,0.0002851526,0.0003075976,0.0006901057,0.0002349738,0.001407464,0.000510679],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006007344,"about_ca_system_score_gemma":0.001075707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008510748,"about_ca_topic_score_gemma":0.002457637,"domain_scores_codex":[0.9997513,0.00007092577,0.00002334226,0.00004588505,0.00003101713,0.00007755448],"domain_scores_gemma":[0.9997457,0.00004254542,0.00004507586,0.00001882832,0.00002495936,0.0001229802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3901384,0.01537051,0.03654216,0.001127778,0.003087991,0.0004712169,0.0001553499,0.003935926,0.05495042,0.0006342815,0.005968163,0.4876179],"study_design_scores_gemma":[0.1673393,0.5340993,0.2251502,0.0003933197,0.006589932,0.002322716,0.000386493,0.01158255,0.0252524,0.001055657,0.02564587,0.0001823684],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927697,0.003931756,0.000117741,0.0003176493,0.0001698154,0.00009990875,0.0003579098,0.00004060005,0.002194971],"genre_scores_gemma":[0.9960824,0.001107136,0.0002798349,0.0003076638,0.00008846412,0.00009011442,0.0007462855,0.00000989073,0.001288206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002764744,"threshold_uncertainty_score":0.009248972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01037545759358799,"score_gpt":0.3512811453665129,"score_spread":0.3409056877729249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}